Amyloid biomarkers: pushing the limits of early detection

Is amyloid-β harmful to the brain? Insights from human imaging studies

(2015) William Jagust   BRAIN

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

(2015) Sandrine Andrieu et al.   LANCET NEUROLOGY

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

(2009) Nigel J. Cairns et al.   ARCHIVES OF NEUROLOGY